Modality
Nanobody
MOA
HPK1i
Target
KRASG12D
Pathway
Wnt
MSGBM
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
~Sep 2020
→ ~Dec 2021
NDA/BLA
Mar 2022
NDA/BLACurrent
NCT05019951
1,917 pts·MS
2022-03→TBD·Completed
1,917 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-139mo agoEMA Filing· GBM
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
NDA/BLA
Complet…
Catalysts
EMA Filing
2025-07-13 · 9mo ago
GBM
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05019951 | NDA/BLA | MS | Completed | 1917 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 |